Galactomannan testing might be useful for early diagnosis of fusariosis

Małgorzata Mikulska1, Elisa Furfaro, Valerio Del Bono

  • 1Division of Infectious Diseases, San Martino University Hospital, 16132 Genoa, Italy. m_mikulska@yahoo.com

Insights

Galactomannan (GM) testing aided early antifungal treatment for a hematopoietic stem cell transplant patient with fusariosis. This indicates GM may help diagnose invasive Fusarium infections in high-risk individuals.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Transplantation Medicine

Background:

  • Galactomannan (GM) is a biomarker primarily used for diagnosing invasive aspergillosis.
  • Hematopoietic stem cell transplantation (HSCT) recipients are at high risk for invasive fungal infections.
  • Fusarium species are emerging opportunistic molds that can cause severe infections in immunocompromised patients.

Observation:

  • A case study involving an HSCT recipient diagnosed with fusariosis is presented.
  • Early antifungal treatment was initiated based on positive GM test results.
  • Laboratory testing revealed that three Fusarium isolates were also positive for GM.

Findings:

  • The presence of GM in a Fusarium infection suggests that this biomarker may not be specific to Aspergillus.
  • Fusarium species, like Aspergillus, can produce galactomannan.
  • GM positivity correlated with invasive Fusarium infection in this HSCT patient.

Implications:

  • Galactomannan testing could potentially be a valuable tool for the early diagnosis of fusariosis in high-risk patient populations.
  • Expanding the diagnostic utility of GM testing may improve outcomes for patients with invasive mold infections.
  • Further research is warranted to validate the role of GM in diagnosing fusariosis and other non-Aspergillus invasive fungal infections.